Supplementary Information for:

Diastereodivergent organocatalysis for the asymmetric synthesis of chiral annulated furans

Charlie Verrier,^{*a*} and Paolo Melchiorre*^{*a,b*}

^{*a*}ICIQ - Institute of Chemical Research of Catalonia, Av. Països Catalans 16, 43007 Tarragona, Spain ^{*b*}ICREA - Catalan Institution for Research and Advanced Studies, Pg. Lluís Companys 23, 08010 Barcelona, Spain

*Correspondence to: pmelchiorre@iciq.es



Table of Contents

| A. General Information | page S3 |
|---|----------|
| General Procedures and Materials | page S3 |
| Determination of Diastereomeric and Enantiomeric Ratios | page S3 |
| B. Representative Procedure for the Synthesis of Cyclic tert-Butyl-Ketoesters | page S3 |
| C. Catalyst Screening and Optimization Studies for the Base Catalyzed Addition | page S4 |
| D. Catalyst Screening and Optimization Studies for the PTC Catalyzed Addition | page S5 |
| E. Optimization of the Marshall conditions for the Silver-Catalyzed Cyclisation | page S6 |
| F. General Procedure for the Base-Catalyzed Process | page S7 |
| G. General Procedure for the PTC-Mediated Process | page S11 |
| H. X-ray Crystallographic Data | page S16 |
| I. NMR spectra | page S19 |
| J. HPLC traces | page S41 |

A. General Information

The ¹H and ¹³C NMR spectra were recorded at 400 MHz and 500 MHz for ¹H and 100 or 125 MHz for ¹³C. The chemical shift (δ) for 1H and 13C are given in ppm relative to residual signals of the solvents (CHCl₃ @ 7.26 ppm ¹H NMR and 77.16 ppm ¹³C NMR). Coupling constants are given in Hertz. The following abbreviations are used to indicate the multiplicity: s, singlet; d, doublet; q, quartet; m, multiplet; bs, broad signal.

High resolution mass spectra (HRMS) were obtained from the ICIQ HRMS unit on Waters GCT gas chromatograph coupled time-of-flight mass spectrometer (GC/MS-TOF) with electrospray ionization (ESI). X-ray data were obtained from the ICIQ X-Ray unit using a Brucker-Nonius diffractometer equipped with an APPEX 2 4K CCD area detector. Optical rotations are reported as follws: $[\alpha]^{n}_{\ D}$ (c in g per 100 mL, solvent).

Unless specified, all the reactions were set up under air using puriss. grade solvents, without any precaution to exclude oxygen or moisture. Chromatographic purification of the products was accomplished using force-flow chromatography (FC) on silica gel (60-200 mesh). Thin layer chromatography (TLC) analysis were carried out on Merck precoated TLC plates (silica gel 60 GF₂₅₄, 0.25 mm), using UV light as the visualizing agent and acidic ceric ammonium molybdate or aqueous basic potassium permanganate as stain developing solutions. Organic solutions were concentrated under reduced pressure on a Buchi rotary evaporator.

The authors are indebted to the team of the Research Support Area at ICIQ and to Grace Fox for proof-reading the manuscript.

Determination of Diastereoisomeric ratios. The diastereoisomeric ratios were determined by ¹H NMR of the crude reaction mixtures after silver-mediated cyclization, and further confirmed by ¹H NMR of the purified compounds.

Determination of Enantiomeric Purity: HPLC analyses on chiral stationary phases were performed on an Agilent 1200-series instrumentation. Daicel Chiralpack AD-H and IA-3, hexane, *i*Pr-OH and/or DCM as the eluent were used. HPLC traces were compared to racemic samples prepared using benzyltriethylammonium chloride as the achiral catalyst.

Determination of yield and conversion in the optimization studies. The conversion of the starting material and the yield of products during the optimization studies were determined by ¹H NMR analysis adding to the crude reaction mixture 1,4-dinitrobenzene as the internal standard (δ 8.40 ppm (s, 4H).

Materials. Commercial grade reagents and solvents were purchased from sigma-Aldrich, Fluka, Alfa Aesar and used as received, without further purifications. The 2-alkynyl-enones $\mathbf{1}^1$ were synthesized according to literature procedures.

B. Representative Procedure for the Synthesis of the Cyclic tert-Butyl-Ketoesters 2

NaH (5.2 mmol, 210 mg, 2.2 eq., 60% dispersion in mineral oil) and anhydrous dimethyl carbonate (*DMC*, 10 mL) were added sequentially to a dry three-necked flask equipped with a septum, condenser, argon inlet, and a large stirring egg. The indan-1-one derivative A (2.37 mmol, 1 eq), partially solubilized in anhydrous dimethyl carbonate (10 mL), was added *via* a syringe pump over the course of 30 minutes (Scheme S1). The heterogeneous mixture was brought to reflux (80 °C),

¹T. Yao, X. Zhang and R. C. Larock *J. Am. Chem. Soc.* **2004**, *126*, 11164-11165.

and heated overnight at this temperature. The reaction was allowed to cool and cautiously quenched at 0°C under an argon atmosphere with H₂O (10 mL). The mixture was transferred to a separative funnel with EtOAc while adding additional 50 mL of 1M HCl. The reaction was extracted with EtOAc (50 mL x 3) and the combined organic layers washed with a saturated brine solution before being dried over solid anhydrous magnesium sulfate and concentrated. The crude material was then dissolved in toluene (20 mL), and *t*BuOH (30 eq, 71.1 mmol, 6.5 mL), and dibutyl-tin oxide (0.2 eq, 118 mg) was added. The flask was fitted with a condenser and the heterogeneous mixture was heated at 115°C until the starting methyl ester **B** was fully consumed (12-36 h), as judged by TLC. The mixture was allowed to cool to room temperature and concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (eluent Et₂O/Hexane1:9 to 2:8) to yield the pure keto-ester **2**.



Scheme S1: Synthesis of cyclic *tert*-butyl-ketoesters 2.



C. Catalyst Screening and Optimization Studies for the Base Catalyzed Addition

Figure S1: General Base Catalysts Screening; the minor diastereoisomer 5a is not shown

Table S1. Effect of the concentration on the quinine-catalyzed reaction^a



^{*a*} Reactions performed on a 0.05 mmol scale using 1.2 equiv of **2a**. After 48 hours, the 4,5'-addition was quenched by filtration through a pad of silica. Upon evaporation of the solvent, the cycloisomerization of the intermediate **3a** was conducted by dissolving the crude residue in 0.5 mL of AcOEt and adding 10 mol% of AgNO₃. ^{*b*} Yield of the isolated products **4a**. ^{*c*} Diastereomeric ratio determined by ¹H NMR analysis of the crude mixture upon cycloisomerization.

D. Catalyst Screening and Optimization Studies for the PTC-mediated Addition



Figure S2: PTC Catalysts Screening; the minor diastereoisomer 4a is not shown

Table S2. Refinements of the Conditions for the PTC-mediated Addition^a



| entry | base | T (°C) | x (M) | % yield ^b | dr ^c | % ee |
|-------|---------------------------------------|--------|--------------|----------------------|-----------------|------|
| 1 | 33% aq K ₂ CO ₃ | -10 | 0.1 | 72 | 19:1 | 79 |
| 2 | 10% aq K ₂ CO ₃ | -10 | 0.1 | 63 | 17:1 | 79 |
| 3 | 66% aq Cs_2CO_3 | -10 | 0.1 | 80 | 18:1 | 68 |
| 4 | 10% aq Cs_2CO_3 | -10 | 0.1 | 50 | 9:1 | 75 |
| 5 | 33% aq K ₂ CO ₃ | -10 | 0.25 | 89 | 19:1 | 83 |
| 6 | 33% an K2CO2 | -20 | 0.25 | 87 | 19:1 | 87 |

^{*a*} Reactions performed on a 0.05 mmol scale using 1.2 equiv of **2a**. After 24 hours, the 4,5'-addition was quenched by filtration through a pad of silica. Upon evaporation of the solvent, the cycloisomerization of the intermediate **3a** was conducted by dissolving the crude residue in 0.5 mL of AcOEt and adding 10 mol% of AgNO₃. ^{*b*} Yield of the isolated products **5a**. ^{*c*} Diastereomeric ratio determined by ¹H NMR analysis of the crude mixture upon cycloisomerization.

Additional comment: Other solvents (hexane, Et₂O, THF, toluene, MTBE), tested under the reaction conditions detailed in entry 5, provided ee values inferior than 10%.

E. Optimization of the Marshall conditions for the Silver-Catalyzed Cyclisation

Table S3. Optimizing the Silver-Catalyzed Cyclization.



| entry | Silver salt | n mol% | solvent | time (h) | T (°C) | Degradation 3a | % conv 3a to furan ^{<i>a</i>} |
|-------|---------------------|--------|---------|----------|--------|--------------------------|---|
| 1 | AgNO ₃ | 5 | acetone | 14 | 25 | no | 20 |
| 2 | AgSbF ₆ | 5 | acetone | 14 | 25 | no | 5 |
| 3 | Ag_2O | 5 | acetone | 14 | 25 | yes | 45 |
| 4 | Ag-imidazolate/PPh3 | 5 | acetone | 14 | 25 | no | 0 |
| 5 | AgNO ₃ | 10 | acetone | 3 | 40 | no | 75 |
| 6 | AgNO ₃ | 10 | toluene | 3 | 40 | no | 85 |
| 7 | AgNO ₃ | 10 | AcOEt | 3 | 40 | no | >95 |
| 8 | AgNO ₃ | 5 | AcOEt | 2 | 70 | yes | >95 |

^{*a*} Determined by ¹H NMR analysis of the crude mixture upon cycloisomerization.

F. General Procedures for the Base-Catalyzed Process (Table 2 of the main manuscript)

All the reactions were carried out in DCM (synthesis grade, >99%), without any precaution to exclude air and moisture (open air chemistry on the benchtop). An ordinary vial equipped with a Teflon-coated stir bar and a plastic screw cap was charged with the 2-alkynyl enone **1** (0.2 mmol), the ketoester **2** (1.2 eq) and quinine (3.2 mg, 5 mol%, 0.05 eq), and cooled down to -10°C. Dichloromethane was then added (0.4 mL, $[1]_0 = 0.5$ M), the vial was sealed and stirring continued over 48 hours. The reaction was diluted with a 1:1 mixture of hexane and ethyl acetate and filtered through a short pad of silica, then rinsed with the same mixture. Solvents were removed under reduced pressure, and replaced by ethyl acetate (2.0 mL, 0.1 M). A solution of silver nitrate (50 mg/mL in MeCN) was then added (68µL, 3.4 mg, 10 mol%, 0.1 eq), the flask covered with an aluminum foil, and the solution was heated at 40°C for 5 h. Solvent was then removed under reduced pressure, and the crude mixture was analyzed by ¹H NMR spectroscopy to determine the distereomeric ratio (dr) of the reaction. The crude material was purified by column chromatography on silica gel to afford the pure annulated furan products **4**.



tert-butyl (*R*)-1-oxo-2-((*R*)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3dihydro-1H-indene-2-carboxylate 4a. Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4a (71 mg, 0.166 mmol, 83% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $ee_{maior} = 99\%$).

When using quinidine as the catalyst of the 4,5'-addition reaction, the opposite enantiomer of the annulated furan 4a was obtained in 82% yield, 18:1 dr, and 98% ee. Major diastereoisomer 4a:

IR (**neat**): 2933, 2861, 1738, 1704 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.79 (ddd, J = 7.8, 1.3, 0.7 Hz, 1H), 7.65 – 7.58 (m, 3H), 7.45 (dt, J = 7.7, 0.9 Hz, 1H), 7.43 – 7.34 (m, 3H), 7.28 – 7.22 (m, 1H), 6.45 (s, 1H), 3.92 – 4.09 (m, 1H), 3.70 (d, J = 17.9 Hz, 1H), 2.86 (d, J = 17.9 Hz, 1H), 2.75 – 2.65 (m, 1H), 2.62 – 2.50 (m, 1H), 2.01 – 1.90 (m, 1H), 1.84 – 1.70 (m, 2H), 1.55 (s, 9H), 0.89 – 0.78 (m, 1H).

¹³C NMR: (125 MHz, CDCl₃) δ 22.4, 23.5, 25.4, 28.2, 33.6, 38.4, 66.0, 82.6, 105.0, 120.6, 123.6, 124.8, 126.5, 127.2, 127.8, 129.0, 131.4, 135.6, 136.0, 152.2, 152.7, 155.0, 170.1, 202.3.

HRMS: Calcd for (C₂₈H₂₈O₄Na)⁺: 451.1880; found: 451.1875.

HPLC: Analysis on a Daicel Chiralpak IA-3, Hex/IPA 96:4, 0.7 mL/min, 20°C, $\lambda = 310$ nm. $\tau_{major} = 8.4 \text{ min}, \tau_{minor} = 11.7 \text{ min}, 99\%$ ee, $[\alpha]_{D}^{26} = -219.2$ (c = 1.0, CHCl₃, 19:1 dr, 99\% ee) *ent-4a*: $[\alpha]_{D}^{26} = +206.8$ (c = 1.0, CHCl₃, 18:1 dr, 98\% ee)



tert-butyl (*R*)-1-oxo-2-((*R*)-2-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 4b. Following the general procedure, 2-alkynyl enone 1b (42 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4b (66 mg, 0.15 mmol, 75% yield) as a white solid (12:1 mixture of inseparable diastereoisomers, $ee_{major} = 97\%$).

Major diastereoisomer **4b**:

IR (neat): 2926, 2851, 1740, 1704 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.78 (dt, J = 7.8, 1.2 Hz, 1H), 7.62 (td, J = 7.4, 1.2 Hz, 1H), 7.60 – 7.56 (m, 2H), 7.51 (dt, J = 7.8, 1.0 Hz, 1H), 7.39 (ddd, J = 7.8, 7.1, 1.0 Hz, 1H), 7.37 – 7.32 (m, 2H), 7.20 (ddt, J = 7.8, 7.0, 1.2 Hz, 1H), 6.40 (s, 1H), 4.00 (d, J = 17.4 Hz, 1H), 3.92 (dt, J = 10.9, 1.5 Hz, 1H), 3.18 (d, J = 17.4 Hz, 1H), 2.96 – 2.65 (m, 1H), 2.86 – 2.77 (m, 1H), 1.97 – 1.82 (m, 2H), 1.71 – 1.59 (m, 1H), 1.50 – 1.42 (m, 2H), 1.41 (s, 9H), 1.17 (dtd, J = 13.7, 11.4, 2.4 Hz, 1H).

¹³C NMR: (125 MHz, CDCl₃) δ 202.6, 169.6, 155.1, 154.1, 149.8, 135.9, 135.7, 131.4, 128.9, 127.9, 127.0, 126.6, 124.9, 124.3, 123.4, 106.8, 82.6, 67.0, 41.6, 34.1, 30.2, 30.1, 28.8, 28.0, 26.0. **HRMS:** Calcd for (C₂₉H₃₁O₄)⁺: 443.2217; found: 443.2216.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM 85:15, flow rate 1.0 mL/min, 20°C, $\lambda = 290$ nm. $\tau_{major} = 5.4$ min, $\tau_{minor} = 5.9$ min, 97% ee. $[\alpha]_{D}^{26} = -211.5$ (c = 1.0, CHCl₃, 12:1 dr, 97% ee)



tert-butyl (*R*)-2-((*R*)-2-(4-methoxyphenyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1-oxo-2,3-dihydro-1H-indene-2-carboxylate 4c. Following the general procedure, 2-alkynyl enone 1c (45 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1.2 eq) were reacted to afford, after column chromatography (eluent MTBE/hexane 1:9), the product 4c (76 mg, 0.166 mmol, 83% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $ee_{major} = 99\%$).

Major diastereoisomer **4**c: **IR (neat):** 2934, 2847, 1739, 1704 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.78 (dt, J = 7.7, 1.0 Hz, 1H), 7.60 (td, J = 7.5, 1.2 Hz, 1H), 7.57 – 7.50 (m, 2H), 7.47 – 7.42 (m, 1H), 7.39 (ddd, J = 7.7, 7.2, 1.0 Hz, 1H), 6.96 – 6.88 (m, 2H), 6.31 (s, 1H), 4.06 – 3.95 (m, 1H), 3.85 (s, 3H), 3.69 (d, J = 17.9 Hz, 1H), 2.86 (d, J = 17.9 Hz, 1H), 2.72 – 2.62 (m, 1H), 2.62 – 2.40 (m, 1H), 1.98 – 1.85 (m, 1H), 1.81 – 1.68 (m, 2H), 1.55 (s, 9H), 0.89 – 0.76 (m, 1H).

¹³C NMR: (**75** MHz, CDCl₃) δ 202.3, 170.1, 159.1, 155.1, 152.3, 151.9, 136.0, 135.6, 127.8, 126.5, 125.0, 124.8, 124.5, 120.4, 114.4, 103.4, 82.6, 66.0, 55.6, 38.5, 33.6, 28.2, 25.4, 23.4, 22.4. **HRMS:** Calcd for $(C_{29}H_{31}O_5)^+$: 459.2166, found: 443.2161.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent Hex/IPA 96:4, flow rate 1.5 mL/min, 20°C, $\lambda = 290$ nm. $\tau_{major} = 4.7$ min, $\tau_{minor} = 6.9$ min, 99% ee. $[\alpha]_{D}^{26} = -293.3$ (c = 1.0, CHCl₃, 19:1 dr, 99% ee).



tert-butyl (*R*)-1-oxo-2-((R)-2-(4-(trifluoromethyl)phenyl)-4,5,6,7tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 4d. Following the general procedure, 2-alkynyl enone 1d (53 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4d (89 mg, 0.18 mmol, 90% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $ee_{major} >99\%$ ee).

^{4d} Major diastereoisomer **4d**: **IR (neat):** 2934, 2861, 1738, 1705, 1323 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.77 (dt, J = 7.7, 0.9 Hz, 1H), 7.69 – 7.64 (m, 2H), 7.62 – 7.56 (m, 3H), 7.43 (dt, J = 7.7, 0.9 Hz, 1H), 7.40 – 7.34 (m, 1H), 6.54 (s, 1H), 4.05 – 3.92 (m, 1H), 3.67 (d, J = 17.8 Hz, 1H), 2.83 (d, J = 17.8 Hz, 1H), 2.74 – 2.63 (m, 1H), 2.56 (m, 1H), 1.99 – 1.88 (m, 1H), 1.79 – 1.68 (m, 2H), 1.52 (s, 9H), 0.82 (tdd, J = 13.3, 11.0, 3.1 Hz, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 202.1, 170.1, 154.9, 154.1, 150.8, 136.0, 135.7, 134.5, 128.7 (q, J_{C-F} = 32 Hz) 127.9, 127.8, 126.0 (q, J = 4 Hz), 125.6, 125.0 (d, J_{C-F} = 205 Hz), 123.5, 121.0, 107.1, 82.7, 65.9, 38.3, 33.6, 28.1, 25.3, 23.5, 22.3.

HRMS: Calcd for $(C_{29}H_{27}F_3NaO_4)^+$: 519.1754, found 519.1776.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent Hex/IPA 96:4, flow rate 1.0 mL/min, 20°C, $\lambda = 290$ nm. $\tau_{major} = 5.8$ min, $\tau_{minor} = 7.2$ min, >99% ee. $[\alpha]_{D}^{26} = -310.5$ (c = 1.0, CHCl₃, 19:1 dr, >99% ee).



tert-butyl (*R*)-1-oxo-2-((*R*)-2-(p-tolyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3dihydro-1H-indene-2-carboxylate 4e. Following the general procedure, 2-alkynyl enone 1e (53 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4e (74 mg, 0.166 mmol, 83% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $ee_{major} = 99\%$).

Major diastereoisomer **4e**:

IR (neat): 2926, 2860, 1739, 1705 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.76 (dt, J = 7.7, 0.9 Hz, 1H), 7.58 (td, J = 7.5, 1.2 Hz, 1H), 7.51 – 7.45 (m, 2H), 7.42 (dt, J = 7.7, 0.9 Hz, 1H), 7.37 (ddd, J = 7.8, 7.1, 1.0 Hz, 1H), 7.20 – 7.12 (m, 2H), 6.36 (s, 1H), 3.98 (m, 1H), 3.67 (d, J = 17.9 Hz, 1H), 2.84 (d, J = 17.9 Hz, 1H), 2.71 – 2.61 (m, 1H), 2.61 – 2.48 (m, 1H), 2.35 (s, 3H), 1.97 – 1.86 (m, 1H), 1.80 – 1.66 (m, 2H), 1.52 (s, 9H), 0.86 – 0.73 (m, 1H).

¹³C NMR: (**126** MHz, CDCl₃) δ 202.3, 170.1, 155.1, 152.5, 152.3, 137.0, 136.0, 135.6, 129.7, 128.7, 127.8, 126.5, 124.8, 123.6, 120.5, 104.3, 82.6, 66.0, 38.5, 33.6, 28.2, 25.4, 23.5, 22.4, 21.6. **HRMS**: Calcd for (C₂₉H₃₁O₄)⁺: 443.2217; found 443.2215.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent Hex/IPA 98:2, flow rate 1.0 mL/min, 30°C, $\lambda = 290$ nm. $\tau_{major} = 6.6$ min, $\tau_{minor} = 10.2$ min, 99% ee. $[\alpha]_{D}^{26} = -280.13$ (c = 1.0, CHCl₃, 19:1 dr, 99% ee).



tert-butyl (*R*)-2-((*R*)-2-(cyclohex-1-en-1-yl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1-oxo-2,3-dihydro-1H-indene-2-carboxylate 4f. Following the general procedure, 2-alkynyl enone 1f (41 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4f (25 mg, 0.05 mmol, 25% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $ee_{major} = 95\%$).

Major diastereoisomer 4f:

IR (neat): 2926, 2855, 1739, 1705 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.74 (dt, J = 7.8, 1.0 Hz, 1H), 7.60 – 7.55 (m, 1H), 7.41 (dt, J = 7.8, 1.0 Hz, 1H), 7.38 – 7.32 (m, 1H), 6.23 (dt, J = 4.2, 2.4 Hz, 1H), 5.91 (s, 1H), 3.99 – 3.84 (m,1H), 3.63 (d, J = 17.8 Hz, 1H), 2.78 (d, J = 17.9 Hz, 1H), 2.57 (dd, J = 16.8, 5.9 Hz, 1H), 2.57 – 2.41 (m, 1H), 2.26 – 2.14 (m, 4H), 1.95 – 1.81 (m, 1H), 1.77 – 1.60 (m, 6 H), 1.49 (s, 9H), 0.81 – 0.66 (m, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 201.3, 169.0, 154.1, 152.9, 150.5, 135.0, 134.5, 126.8, 126.5, 125.5, 123.8, 120.7, 118.6, 102.6, 81.5, 65.1, 37.5, 32.6, 27.2, 24.5, 24.4, 24.2, 22.4, 21.8, 21.7, 21.4.

HRMS: Calcd for (C₂₈H₃₂NaO₄)⁺: 455.2193; found: 455.2198.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM/IPA 89.5:15:0.5, flow rate 0.7 mL/min, 20°C, $\lambda = 254$ nm. $\tau_{major} = 6.9$ min, $\tau_{minor} = 7.8$ min, 95% ee. $[\alpha]_{D}^{26} = -139.6$ (c = 1.0, CHCl₃, 19:1 dr, 95% ee).



tert-butyl(R)-5-methoxy-1-oxo-2-((R)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate4g:Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) andketoester 2g (63 mg, 1,2 eq) were reacted to afford, after column chromatography(eluent AcOEt/hexane 1:9), the product 4g (57 mg, 0.124 mmol, 62% yield) as acolorless oil (19:1 mixture of inseparable diastereoisomers, $ee_{major} = 99\%$).Major diastereoisomer 4g:4g:

IR (neat): 2932, 2851, 1733, 1699, 1597 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃)** δ 7.71 (d, *J* = 8.6 Hz, 1H), 7.63 – 7.57 (m, 2H), 7.37 (dd, *J* = 8.4, 7.1 Hz, 2H), 7.27 – 7.21 (m, 1H), 6.92 (dd, *J* = 8.6, 2.3 Hz, 1H), 6.86 (d, *J* = 2.2 Hz, 1H), 6.44 (s, 1H), 4.03 – 3.94 (m, 1H), 3.88 (s, 3H), 3.63 (d, *J* = 17.9 Hz, 1H), 2.79 (d, *J* = 17.9 Hz, 1H), 2.74 – 2.64 (m, 1H), 2.64 – 2.50 (m, 1H), 2.00 – 1.89 (m, 1H), 1.83 – 1.70 (m, 2H), 1.55 (s, 9 H), 0.83 (tdd, *J* = 13.3, 10.0, 2.6 Hz, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 200.1, 170.4, 166.1, 158.0, 152.7, 152.2, 131.4, 129.2, 129.0, 127.2, 126.5, 123.6, 120.7, 116.0, 109.5, 105.0, 82.5, 66.2, 56.0, 38.2, 33.6, 28.2, 25.3, 23.5, 22.4. **HRMS**: Calcd for (C₂₉H₃₀NaO₅)⁺: 481.1985; found: 481.1988.

HPLC: Analysis on a Daicel Chiralpak AD-H column, eluent Hex/IPA 97.3, flow rate 1.5 mL/min, 30° C, $\lambda = 310$ nm. $\tau_{major} = 6.9$ min, $\tau_{minor} = 20.1$ min, 99% ee. $[\alpha]^{26}{}_{D} = -282.53$ (c = 1.0, CHCl₃, 19:1 dr, 99% ee).



tert-butyl (*R*)-6-bromo-1-oxo-2-((*R*)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4yl)-2,3-dihydro-1H-indene-2-carboxylate 4h. Following the general procedure, 2alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and ketoester 2h (63 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4h (83 mg, 0.164 mmol, 82% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $ee_{major} = 98\%$). Major diastereoisomer 4h:

IR (neat): 2928, 2854, 1740, 1706 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.88 (d, J = 1.9 Hz, 1H), 7.68 (dd, J = 8.1, 1.9 Hz, 1H), 7.61 – 7.55 (m, 2H), 7.37 – 7.33 (m, 2H), 7.31 (dd, J = 8.1, 0.8 Hz, 1H), 7.24 – 7.20 (m, 1H), 6.39 (s, 1H), 3.90 – 3.99 (m, 1H), 3.60 (d, J = 18.0 Hz, 1H), 2.77 (d, J = 18.0 Hz, 1H), 2.67 (dd, J = 16.6, 5.7 Hz, 1H), 2.62 – 2.50 (m, 1H), 1.96 – 1.84 (m, 1H), 1.80 – 1.66 (m, 2H), 1.52 (s, 9H), 0.79 (m, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 200.9, 169.6, 153.6, 152.8, 152.3, 138.3, 137.8, 131.3, 129.0, 128.1, 127.7, 127.3, 123.6, 122.0, 120.3, 104.8, 83.0, 66.6, 38.5, 33.3, 28.2, 25.4, 23.4, 22.4.

HRMS: Calcd for (C₂₈H₂₇BrNaO₄)⁺: 529.0985; found: 529.0986.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/IPA 97.3, flow rate 0.7 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{major} = 5.4$ min, $\tau_{minor} = 7.3$ min, 98% ee. $[\alpha]_{D}^{26} = -157.1$ (c = 1.0, CHCl₃, 19:1 dr, 98% ee).

The relative and absolute configuration for **4h** was unambiguously inferred by anomalous dispersion X-ray crystallographic analysis, see X-ray Crystallographic Data section.



tert-butyl (*R*)-5,6-dimethoxy-1-oxo-2-((*R*)-2-phenyl-4,5,6,7tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 4i: Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and ketoester 2i (70 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent AcOEt/hexane 2:8), the product 4i (65 mg, 0.134 mmol, 67% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $e_{major} = 99\%$).

Major diastereoisomer **4i**:

IR (neat): 2936, 2860, 1733, 1697, 1499 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃)** δ 7.60 – 7.56 (m, 2H), 7.38 – 7.31 (m, 2H), 7.24 – 7.19 (m, 1H), 7.16 (s, 1H), 6.82 (s, 1H), 3.98 – 3.94 (m, 2H), 3.92 (d, *J* = 13.2 Hz, 6H), 3.55 (dd, *J* = 17.6, 0.8 Hz, 1H), 2.72 (dd, *J* = 17.5, 0.8 Hz, 1H), 2.67 (dd, *J* = 17.0, 5.2 Hz, 1H), 2.62 – 2.49 (m, 1H), 1.96 – 1.89 (m, 1H), 1.80 – 1.68 (m, 2H), 1.53 (s, 9H), 0.85 – 0.74 (m, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 200.6, 170.4, 156.3, 152.3, 152.1, 150.6, 149.9, 131.4, 128.9, 128.6, 127.2, 123.6, 120.8, 107.3, 105.04, 105.03, 82.5, 66.3, 56.5, 56.4, 38.1, 33.3, 28.2, 25.3, 23.5, 22.4.

HRMS: Calcd for $(C_{30}H_{32}NaO_6)^+$: 511.2091, found 511.2095.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent Hex/IPA 97.3, flow rate 1.2 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{major} = 7.90$ min, $\tau_{minor} = 17.38$ min, 99% ee. $[\alpha]_{D}^{26} = -291.55$ (*c* = 1.0, CHCl₃, 19:1 dr, 99% ee).



tert-butyl(R)-5,6-dimethoxy-1-oxo-2-((R)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate4j:Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq)and ketoester 2j (59 mg, 1,2 eq) were reacted to afford, after columnchromatography (eluent toluene/hexane 8:2), the product 4j (77 mg, 0.174mmol, 87% yield) as a white solid (20:1 mixture of inseparablediastereoisomers, $ee_{major} = 97\%$). Major diastereoisomer 4j:

IR (neat): 2926, 2859, 1738, 1704 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.61 – 7.54 (m, 3H), 7.40 (ddd, J = 7.8, 1.8, 0.8 Hz, 1H), 7.38 – 7.33 (m, 2H), 7.31 (dd, J = 7.8, 1.0 Hz, 1H), 7.24 – 7.19 (m, 1H), 6.43 (s, 1H), 3.97 (dddd, J = 11.3, 4.5, 2.9, 1.5 Hz, 1H), 3.62 (d, J = 17.8 Hz, 1H), 2.78 (d, J = 17.7 Hz, 1H), 2.71 – 2.62 (m, 1H), 2.50 – 2.60 (m, 1H), 2.40 (s, 3H), 1.97 – 1.86 (m, 1H), 1.79 – 1.64 (m, 2H), 1.53 (s, 9H), 0.87 – 0.74 (m, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 202.3, 170.2, 152.7, 152.4, 152.2, 137.8, 136.9, 136.2, 131.4, 129.0, 127.2, 126.2, 124.7, 123.6, 120.6, 105.0, 82.5, 66.3, 38.4, 33.2, 28.2, 25.3, 23.5, 22.4, 21.4. **HRMS**: Calcd for (C₂₉H₃₀NaO₄)⁺: 465.2036, found 465.2045.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM 85.15, flow rate 0.7 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{major} = 7.8$ min, $\tau_{minor} = 9.4$ min, 97% ee. $[\alpha]^{26}{}_{D} = -282.53$ (c = 1.0, CHCl₃, 19:1 dr, 97% ee).



tert-butyl (*R*)-5,6-dimethoxy-1-oxo-2-((*R*)-2-phenyl-4,5,6,7tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 4k. Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and ketoester 2k (60 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4k (78 mg, 0.175 mmol, 88% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, $ee_{major} = 98\%$).

Major diastereoisomer **4k**:

IR (neat): 2929, 2854, 1739, 1706, 1593 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃)** δ 7.80 – 7.73 (m, 1H), 7.62 – 7.54 (m, 2H), 7.40 – 7.31 (m, 2H), 7.25 – 7.18 (m, 1H), 7.11 – 7.04 (m, 2H), 6.40 (s, 1H), 3.98 (dtd, *J* = 11.3, 2.9, 1.5 Hz, 1H), 3.71 – 3.61 (m, 1H), 2.82 (d, *J* = 18.1 Hz, 1H), 2.72 – 2.63 (m, 1H), 2.62 – 2.48 (m, 1H), 1.98 – 1.88 (m, 1H), 1.80 – 1.67 (m, 2H), 1.53 (s, 9H), 0.86 – 0.73 (m, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 200.3, 169.8, 167.8 (d, $J_{C-F} = 257$ Hz), 158.0 (d, $J_{C-F} = 11.3$ Hz) 152.7, 152.3, 132.4 (d, $J_{C-F} = 1.3$ Hz) 131.3, 129.0, 127.3, 127.3 (d, $J_{C-F} = 10.1$ Hz) 123.6, 120.3, 116.3 (d, $J_{C-F} = 21.4$ Hz),113.2 (d, $J_{C-F} = 21.4$ Hz), 104.8, 82.8, 66.4, 38.3, 33.5, 28.1, 25.4, 23.4, 22.4.

HRMS: Calcd for (C₂₈H₂₇FNaO₄)⁺: 469.1786; found: 469.1785.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM 85.15, flow rate 0.7 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{major} = 8.3$ min, $\tau_{minor} = 10.0$ min, 98% ee. $[\alpha]_{D}^{26} = -265.58$ (c = 1.0, CHCl₃, 19:1 dr, 98% ee).

G. General Procedures for the PTC-mediated Process (Table 3 in the main manuscript)

All the reactions were carried out without any precaution to exclude air and moisture (open air chemistry on the benchtop). An ordinary vial equipped with a Teflon-coated stir bar and a plastic screw cap was charged with the 2-alkynyl enone **1** (0.2 mmol), the ketoester **2** (1.2 eq) and the quinidine-derived phase-transfer catalyst **PTC-QD** (13.4 mg, 0.01 mmol, 5 mol%, 0.05 eq), and cooled down to -20°C. Dichloromethane (0.8 mL, 0.25M) was added followed by 33% aqueous potassium carbonate (160 μ L), the vial was sealed and stirring continued over 24 hours. The reaction was diluted with a 1:1 mixture of hexane and ethyl acetate and filtered on a short pad of silica, then rinsed with the same mixture. Solvents were removed under reduced pressure, and replaced by ethyl acetate (2.0 mL, 0.1 M). A solution of silver nitrate (50 mg/mL in MeCN) was then added (68µL, 3.4 mg, 10 mol%, 0.1 eq), the flask covered with an aluminum foil, and the solution was heated at 40°C for 5 h. Solvent was then removed under reduced pressure, and the crude mixture was analyzed by ¹H NMR spectroscopy to determine the diastereomeric ratio (dr) of the reaction. The crude material was purified by column chromatography on silica gel to afford the pure annulated furan products **5**.



tert-butyl (*S*)-1-oxo-2-((*R*)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3dihydro-1H-indene-2-carboxylate 5a. Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 4a (76.5 mg, 0.178 mmol, 89% yield) as a white solid (19:1 mixture of inseparable diastereoisomers, 87% ee).

When using the quinine derivative **PTC-QN** (10 mol%, 48h of reaction at -20°C) as the catalyst of the 4,5'-addition reaction, the opposite enantiomer of the annulated furan **5a** (*ent*-**5a**) was obtained in 73% yield, 13:1 dr, and 86% ee.

Major diastereoisomer 5a:

IR (neat): 2931, 2859, 1738, 1709 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.87 – 7.81 (m, 1H), 7.54 (td, J = 7.4, 1.2 Hz, 1H), 7.40 – 7.33 (m, 4H), 7.23 (ddd, J = 8.0, 7.1, 1.4 Hz, 2H), 7.12 (td, J = 7.3, 1.3 Hz, 1H), 5.91 (s, 1H), 4.03 – 3.91 (m, 1H), 3.68 (d, J = 16.7 Hz, 1H), 2.85 (d, J = 16.7 Hz, 1H), 2.74 – 2.57 (m, 2H), 2.12 – 1.96 (m, 2H), 1.85 – 1.75 (m, 1H), 1.51 – 1.39 (m, 1H), 1.43 (s, 9H).

¹³C NMR: (125 MHz, CDCl₃) δ 202.6, 168.3, 154.7, 152.7, 151.8, 136.0, 135.5, 131.2, 128.8, 127.8, 127.0, 126.8, 124.6, 123.6, 118.8, 105.2, 82.6, 67.9, 38.5, 32.8, 28.1, 26.9, 23.6, 22.4.

HRMS: Calcd for (C₂₈H₂₈O₄Na)⁺: 451.1880; found: 451.1878.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM 80/20, flow rate 1.0 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{minor} = 6.3$ min, $\tau_{major} = 6.7$ min, 87% ee. $[\alpha]_{D}^{26} = -21.6$ (c = 1.0, CHCl₃, 19:1 dr, 87% ee).

ent-5a: $[\alpha]_{D}^{26} = +26.3$ (*c* = 1.0, CHCl₃, 13:1 dr, 86% ee)

The relative and absolute configuration for **5a** was unambiguously inferred by anomalous dispersion X-ray crystallographic analysis, see X-ray Crystallographic Data section.



tert-butyl (*S*)-1-oxo-2-((*R*)-2-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 5b. Following the general procedure, 2alkynyl enone 1b (42 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), the product 5b (72mg, 0.163 mmol, 81%) as a colorless oil (9.5:1 mixture of unseparable diastereoisomers, 93% ee).

Major diastereoisomer:

IR (neat): 2926, 2854, 1738, 1712 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.76 (dt, J = 7.6, 0.9 Hz, 1H), 7.55 (td, J = 7.5, 1.2 Hz, 1H), 7.44 (dt, J = 7.7, 0.9 Hz, 1H), 7.37 – 7.31 (m, 3H), 7.25 – 7.21 (m, 2H), 7.13 – 7.09 (m, 1H), 6.09 (s, 1H), 4.06 – 3.91 (m, 1H), 3.84 (d, J = 16.7 Hz, 1H), 3.10 (d, J = 16.6 Hz, 1H), 2.90 (t, J = 5.9 Hz, 2H), 1.99 – 1.70 (m, 6H), 1.43 (s, 10H).

¹³C NMR: (125 MHz, CDCl₃) δ 201.9, 168.6, 154.3, 153.8, 150.2, 135.6, 135.5, 131.2, 128.8, 127.8, 126.9, 126.6, 124.8, 123.5, 122.2, 108.1, 82.6, 69.0, 40.6, 33.9, 31.1, 28.3, 28.1, 27.6, 26.1. **HRMS**: Calcd for (C₂₉H₃₀NaO₄)⁺: 465.2036; found: 465.2057.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM 85:15, flow rate 1.0 mL/min, 20°C, $\lambda = 290$ nm. $\tau_{minor} = 6.9$ min , $\tau_{major} = 7.3$ min, 93% ee. $[\alpha]^{26}{}_{D} = -5.1$ (c = 1.0, CHCl₃, 9.5:1 dr, 93% ee).



tert-butyl (*S*)-2-((*R*)-2-(4-methoxyphenyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1oxo-2,3-dihydro-1H-indene-2-carboxylate 5c. Following the general procedure, 2alkynyl enone 1c (45 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq were reacted to afford, after column chromatography (eluent MTBE/hexane 1:9), the product 5c (80 mg, 0.174 mmol, 87 %) after column chromatography (Eluent MTBE/hexane 1:9) as a white solid (19:1 mixture of unseparable diastereoisomers, $ee_{maior} = 89\%$).

Major diastereoisomer:

IR (neat): 2934, 2854, 1737, 1709, 1499 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃)** δ 7.83 (d, J = 7.6 Hz, 1H), 7.53 (td, J = 7.6, 1.2 Hz, 1H), 7.41 – 7.33 (m, 2H), 7.28 (d, J = 8.8 Hz, 2H), 6.77 (d, J = 8.8 Hz, 2H), 5.77 (s, 1H), 4.05 – 3.90 (m, 1H), 3.75 (s, 3H), 3.67 (d, J = 16.8 Hz, 1H), 2.85 (d, J = 16.8 Hz, 1H), 2.72 – 2.55 (m, 2H), 2.12 – 1.98 (m, 2H), 1.86 – 1.72 (m, 1H), 1.50 – 1.37 (m, 1H), 1.43 (s, 9H).

¹³C NMR: (100 MHz, CDCl₃) δ 202.6, 168.3, 158.9, 154.7, 151.9, 151.8, 136.0, 135.5, 127.7, 126.7, 125.0, 124.5, 124.4, 118.7, 114.2, 103.6, 82.5, 67.9, 55.5, 38.5, 32.8, 28.1, 26.9, 23.6, 22.4. **HRMS**: Calcd for $(C_{29}H_{31}O_5)^+$: 459.2166; found: 459.2171.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent Hex/IPA 96:4, flow rate 1.5 mL/min, 20°C, $\lambda = 290$ nm. $\tau_{minor} = 9.3$ min, $\tau_{major} = 11.4$ min, 89% ee. $[\alpha]^{26}_{D} = -53.3$ (c = 1.0, CHCl₃, 19:1 dr, 89% ee).



tert-butyl (S)-1-oxo-2-((R)-2-(4-(trifluoromethyl)phenyl)-4,5,6,7tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 5d: Following the general procedure, 2-alkynyl enone 1d (53 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2) product 5d (84 mg, 0.169 mmol, 84 %) after column chromatography (eluent toluene/hexane 8:2) as a white solid (8:1 mixture of unseparable diastereoisomers, ee_{major} = 81%).

Major diastereoisomer:

IR (neat): 2932, 2860, 1739, 1712 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃) δ 7.87 (dt, J = 7.6, 1.1 Hz, 1H), 7.57 (ddd, J = 7.6, 7.1, 1.1 Hz, 1H), 7.51 – 7.38 (m, 7H), 6.04 (s, 1H), 4.01 (ddt, J = 9.2, 5.2, 2.1 Hz, 1H), 2.85 (d, J = 17.0 Hz, 1H), 2.77 – 2.60 (m, 2H), 2.16 – 2.04 (m, 2H), 1.88 – 1.78 (m, 1H), 1.55 – 1.44 (m, 1H), 1.45 (s, 9H).

¹³C NMR: (100 MHz, CDCl₃) δ 202.6, 168.2, 154.6, 154.0, 150.5, 135.9, 135.6, 134.3 (d, $J_{C-F} = 1$ Hz) 127.93, 127.89, 126.5, 125.8 (q, $J_{C-F} = 4$ Hz), 125.7 (d, $J_{C-F} = 217$ Hz) 124.9, 123.5, 119.3, 107.2, 82.7, 67.8, 38.4, 32.9, 28.1, 26.8, 23.7, 22.3.

HRMS: Calcd for $(C_{29}H_{27}F_3NaO_4)^+$: 519.1754; found: 519.1754.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/IPA 96:4, flow rate 1.0 mL/min, 20°C, $\lambda = 290$ nm. $\tau_{minor} = 7.8$ min, $\tau_{major} = 8.4$ min, 81% ee. $[\alpha]_{D}^{26} = -11.7$ (c = 1.0, CHCl₃, 8:1 dr, 81% ee).



tert-butyl (*S*)-1-oxo-2-((*R*)-2-(p-tolyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3dihydro-1H-indene-2-carboxylate 5e. Following the general procedure, 2-alkynyl enone 1e (43 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2),product 5e (73 mg, 0.165 mmol, 82 %) after column chromatography as a white solid (19:1 mixture of unseparable diastereoisomers, $ee_{major} = 91\%$).

⁵⁰ Major diastereoisomer: **IR (neat):** 2929, 2860, 1738, 1712 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.83 (dt, J = 7.8, 0.9 Hz, 1H), 7.55 – 7.50 (m, 1H), 7.39 – 7.33 (m, 2H), 7.26 – 7.23 (m, 2H), 7.05 – 7.01 (m, 2H), 5.85 (s, 1H), 3.97 (ddt, J = 9.3, 4.9, 2.0 Hz, 1H), 3.69 – 3.65 (d, J = 17.0 Hz, 1H), 2.85 (d, J = 17.0 Hz, 1H), 2.71 – 2.55 (m, 2H), 2.26 (s, 3H), 2.10 – 1.99 (m, 2H), 1.85 – 1.73 (m, 1H), 1.50 – 1.39 (m, 1H), 1.43 (s, 9H).

¹³C NMR: (126 MHz, CDCl₃) δ 202.6, 168.3, 154.7, 152.2, 152.0, 136.8, 136.0, 135.5, 129.4, 128.6, 127.7, 126.7, 124.6, 123.6, 118.7, 104.4, 82.5, 67.9, 38.5, 32.8, 28.1, 26.9, 23.6, 22.4, 21.5. **HRMS**: Calcd for (C₂₉H₃₀NaO₄)⁺: 465.2036; found: 465.2045.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/IPA 98:2, flow rate 1.0 mL/min, 30°C, $\lambda = 290$ nm. $\tau_{minor} = 9.5$ min, $\tau_{major} = 12.1$ min, 91% ee. $[\alpha]^{26}_{D} = -24.9$ (c = 1.0, CHCl₃, 19:1 dr, 91% ee).



tert-butyl (S)-2-((R)-2-(cyclohex-1-en-1-yl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1-oxo-2,3-dihydro-1H-indene-2-carboxylate 5f: Following a modified general procedure (reaction at -10 °C using 1.6 mol% of PTC-QD), 2-alkynyl enone 1f (41 mg, 0.2 mmol, 1 eq) and ketoester 2a (55 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), product 5f (46 mg, 0.106 mmol, 53 %) as a colorless oil (only one diastereoisomer detected, ee = 93%).

IR (neat): 2926, 2854, 1739, 1714 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃)** δ 7.82 – 7.76 (m, 1H), 7.54 (td, J = 7.5, 1.2 Hz, 1H), 7.42 – 7.30 (m, 2H), 6.12–5.98 (m, 1H), 5.38 (s, 1H), 3.99 – 3.86 (m, 1H), 3.64 (d, J = 16.8 Hz, 1H), 2.79 (d, J = 16.8 Hz, 1H), 2.63 – 2.49 (m, 2H), 2.12 – 1.91 (m, 5H), 1.80 – 1.68 (m, 2H), 1.61 – 1.48 (m, 4H), 1.42 (s, 10H), 0.91 – 0.85 (m, 1H).

¹³C NMR: (126 MHz, CDCl₃) δ 202.6, 168.4, 154.7, 153.4, 151.5, 136.1, 135.3, 127.7, 127.5, 126.8, 124.5, 121.33, 117.9, 103.9, 82.5, 67.8, 38.6, 32.8, 28.2, 26.9, 25.4, 24.9, 23.5, 22.6, 22.5, 22.4.

HRMS: Calcd for $(C_{28}H_{32}NaO_4)^+$: 455.2193; found: 455.2206.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM/IPA 89.5:15:0.5, flow rate 0.7 mL/min, 20°C, $\lambda = 254$ nm. $\tau_{minor} = 8.9$ min, $\tau_{major} = 9.4$ min, ee = 93%. [α]²⁶_D = -35.3 (c = 1.0, CHCl₃, 93% ee).



tert-butyl (S)-6-bromo-1-oxo-2-((R)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 5h.

Following a modified general procedure (reaction at -10 °C using 1.6 mol% of **PTC-QD**), 2-alkynyl enone **1a** (39 mg, 0.2 mmol, 1 eq) and ketoester **2g** (75 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), product **5h** (79 mg, 0.156 mmol, 78 %) as a colorless oil (11:1 mixture of unseparable diastereoisomers, $ee_{major} = 77$ %).

Major diastereoisomer:

IR (neat): 2930, 2858, 1736, 1710 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃)** δ 7.96 (dd, J = 2.0, 0.6 Hz, 1H), 7.64 (dd, J = 8.1, 2.0 Hz, 1H), 7.41 – 7.37 (m, 2H), 7.29 – 7.25 (m, 3H), 7.17 – 7.12 (m, 1H), 5.88 (s, 1H), 4.04 – 3.90 (m, 1H), 3.62 (d, J

= 16.9 Hz, 1H), 2.82– 2.74 (m, 1H), 2.72 – 2.57 (m, 2H), 2.09 – 1.99 (m, 2H), 1.85 – 1.72 (m, 1H), 1.50 – 1.40 (m, 1H), 1.43 (s, 9H).

¹³C NMR: (126 MHz, CDCl₃) δ 201.2, 167.9, 153.3, 152.8, 152.1, 138.3, 137.7, 131.1, 128.4, 128.4, 127.4, 127.2, 123.7, 121.9, 118.6, 104.9, 82.9, 68.6, 38.4, 32.5, 28.1, 26.9, 23.6, 22.3. **HRMS**: Calcd for ($C_{28}H_{27}BrNaO_4$)⁺: 529.0985; found: 529.0982.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/IPA 97:3, flow rate 0.7 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{minor} = 6.8$ min, $\tau_{major} = 8.3$ min, 77% ee. $[\alpha]^{26}{}_{D} = +43.5$ (c = 1.0, CHCl₃, 11:1 dr, 77% ee).



tert-butyl (S)-5,6-dimethoxy-1-oxo-2-((R)-2-phenyl-4,5,6,7tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 5i. Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and ketoester 2i (70 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent AcOEt/hexane 2:8), product 5i (61 mg, 0.124 mmol, 62%) as a colorless oil (1:16 mixture of unseparable diastereoisomers, $ee_{major} =$ 73%).

Major diastereoisomer:

IR (neat): 2936, 2860, 1733, 1697 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.42 – 7.38 (m, 2H), 7.28 – 7.24 (m, 3H), 7.15 (ddt, J = 7.9, 6.9, 1.3 Hz, 1H), 6.82 (s, 1H), 5.97 (s, 1H), 4.0 – 3.95 (m, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 3.60 (d, J = 16.5 Hz, 1H), 2.78 – 2.73 (m, 1H), 2.73 – 2.62 (m, 2H), 2.15 – 1.98 (m, 2H), 1.87 – 1.76 (m, 1H), 1.52 – 1.40 (m, 1H) 1.47 (s, 9H).

¹³C NMR: (126 MHz, CDCl₃) δ 200.8, 168.7, 156.1, 152.6, 151.8, 150.3, 149.8, 131.3, 128.8, 128.5, 127.0, 123.56, 118.9, 107.7, 105.2, 105.0, 82.4, 77.6, 68.0, 56.5, 38.2, 32.5, 28.2, 27.0, 23.6, 22.4.

HRMS: Calcd for $(C_{30}H_{32}NaO_6)^+$: 511.2091; found: 511.2094.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/IPA 97:3, flow rate 1.2 mL/min, 30° C, $\lambda = 310$ nm. $\tau_{minor} = 18.1$ min, $\tau_{major} = 20.5$ min, 73% ee. $[\alpha]_{D}^{26} = -32.8$ (C= 1.0, CHCl₃, 16:1

dr, 73% ee).

tert-butyl (S)-5,6-dimethoxy-1-oxo-2-((R)-2-phenyl-4,5,6,7tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 5j. Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and ketoester 2j (60 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), product 5j (77 mg, 0.174 mmol, 87 %) as a colorless oil (19:1 mixture of unseparable diastereoisomers, $ee_{major} =$ 87%).

Major diastereoisomer:

IR (neat): 2934, 2860, 1737, 1708 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.66 (dt, J = 1.7, 0.9 Hz, 1H), 7.43 – 7.36 (m, 3H), 7.31 – 7.24 (m, 3H), 7.17 – 7.12 (m, 1H), 5.96 (s, 1H), 4.04 – 3.96 (m, 1H), 3.65 (d, J = 16.7 Hz, 1H), 2.81 (d, J = 16.7 Hz, 1H), 2.75 – 2.60 (m, 2H), 2.43 (s, 3H), 2.15 – 2.03 (m, 2H), 1.88 – 1.75 (m, 1H), 1.54 – 1.42 (m, 1H), 1.46 (s, 9H).

¹³C NMR: (126 MHz, CDCl₃) δ 202.6, 168.4, 152.7, 152.1, 151.8, 137.6, 136.8, 136.1, 131.3, 128.7, 127.0, 126.4, 124.5, 123.6, 118.9, 105.2, 82.4, 68.2, 38.3, 32.4, 28.1, 26.9, 23.6, 22.4, 21.41. HRMS: Calcd for ($C_{29}H_{30}NaO_4$)⁺: 465.2036; found: 465.2028.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM 85:15, flow rate 0.7 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{minor} = 10.2$ min, $\tau_{major} = 12.6$ min, 87% ee. $[\alpha]_{D}^{26} = +10.52$ (c = 1.0, CHCl₃, 19:1 dr, 87% ee).

(S)-5,6-dimethoxy-1-oxo-2-((R)-2-phenyl-4,5,6,7-



tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate5k.Following the general procedure, 2-alkynyl enone 1a (39 mg, 0.2 mmol, 1 eq) and
ketoester 2k (60 mg, 1,2 eq) were reacted to afford, after column chromatography
(eluent toluene/hexane 8:2), product 5k (77 mg, 0.174 mmol, 87 %) as a colorless
oil (1:15 mixture of unseparable diastereoisomers, $ee_{major} = 85\%$).Major diastereoisomer:

IR (neat): 2935, 2860, 1738, 1712 cm⁻¹.

tert-butvl

¹**H** NMR (500 MHz, CDCl₃) δ 7.85 (dd, J = 8.3, 5.2 Hz, 1H), 7.40 – 7.35 (m, 2H), 7.26 – 7.22 (m, 2H), 7.16 – 7.11 (m, 1H), 7.10 – 7.03 (m, 2H), 5.91 (s, 1H), 4.03 – 3.94 (m, 0H), 3.67 (d, J = 17.0 Hz, 1H), 2.88 – 2.80 (m, 1H), 2.74 – 2.51 (m, 2H), 2.11 – 1.99 (m, 2H), 1.85 – 1.75 (m, 1H), 1.49 – 1.38 (m, 1H), 1.44 (s, 9H).

¹³C NMR: (126 MHz, CDCl₃) δ 200.7, 168.1, 167.7 (d, $J_{C-F} = 255$ Hz), 157.8 (d, $J_{C-F} = 10$ Hz) 152.8, 152.0, 132.3 (d, $J_{C-F} = 1.2$ Hz) 131.2, 128.8, 127.2, 126.9 (d, $J_{C-F} = 12$ Hz) 123.6, 118.7, 116.2 (d, $J_{C-F} = 24$ Hz), 113.5 (d, $J_{C-F} = 22.5$ Hz) 105.0, 82.8, 68.2, 38.3, 32.8, 28.1, 26.9, 23.6, 22.3.

HRMS: Calcd for (C₂₈H₂₇FNaO₄)⁺: 469.1786; found: 469.1777.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent hex/DCM 85:15, flow rate 0.7 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{major} = 12.2$ min, $\tau_{minor} = 13.0$ min, 85% ee. $[\alpha]_{D}^{26} = -18.1$ (c = 1.0, CHCl₃, 15:1 dr, 85% ee).



tert-butyl (S)-5-bromo-1-oxo-2-((R)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-2,3-dihydro-1H-indene-2-carboxylate 5l.

Following the general procedure, 2-alkynyl enone **1a** (39 mg, 0.2 mmol, 1 eq) and ketoester **2l** (75 mg, 1,2 eq) were reacted to afford, after column chromatography (eluent toluene/hexane 8:2), product **5l** (71 mg, 0.14 mmol, 70%) as a colorless oil (19:1 mixture of unseparable diastereoisomers, $ee_{major} = 83$ %).

Major diastereoisomer:

IR (neat): 2930, 2866, 1731, 1698 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃) δ 7.69 (dd, J = 8.2, 0.6 Hz, 1H), 7.57 (dd, J = 1.7, 0.8 Hz, 1H), 7.53 – 7.50 (m, 1H), 7.40 – 7.35 (m, 2H), 7.28 – 7.22 (m, 2H), 7.16 – 7.11 (m, 1H), 5.89 (s, 1H), 4.00 – 3.95 (m, 1H), 3.66 (d, J = 17.1 Hz, 1H), 2.84 (d, J = 16.9, 1H), 2.73 – 2.58 (m, 2H), 2.12 –2.01 (m, 2H), 1.86 – 1.74 (m, 1H), 1.44 (s, 9H), 0.91 – 0.84 (m, 1H).

¹³C NMR: (125 MHz, CDCl₃) δ 201.4, 167.9, 156.2, 152.8, 152.1, 134.8, 131.5, 131.1, 130.1, 128.8, 127.2, 125.7, 123.6, 118.6, 104.9, 82.9, 68.1, 38.4, 32.6, 30.0, 28.1, 26.8, 23.6, 22.3.

HRMS: Calcd for $(C_{28}H_{27}BrNaO_4)^+$: 529.0985; found: 529.0988.

HPLC: Analysis on a Daicel Chiralpak IA-3 column, eluent Hex/DCM 75:25, flow rate 0.5 mL/min, 30°C, $\lambda = 310$ nm. $\tau_{major} = 10.0$ min, $\tau_{minor} = 10.6$ min, 83% ee. $[\alpha]_{D}^{26} = -77.6$ (c = 1.0, CHCl₃, 19:1 dr, 83% ee).

H. X-ray Crystallographic Data

Single Crystal X-ray Diffraction Data for compound 4h (synthesized using quinine)

X-ray structure determinations: Crystals of compound **4h** were obtained from a mixture of DCM and hexane at 0 degree. *Data Collection*. Measurements were made on a Bruker-Nonius diffractometer equipped with an APPEX 2 4K CCD area detector, a FR591 rotating anode with $Mo_{K\alpha}$ radiation, Montel mirrors and a Cryostream Plus low temperature device (T = 100K). Full-sphere data collection was used with ω and φ scans.





Crystal data for 4h at 100 K: CCDC 1046068

| Identification code | mo_CV438_0m |
|---|---|
| Empirical formula | C28 H27 Br O4 |
| Formula weight | 507.40 |
| Temperature | 100(2) K |
| Wavelength | 0.71073 Å |
| Crystal system | Orthorhombic |
| Space group | P2(1)2(1)2(1) |
| Unit cell dimensions | $a = 8.7857(6)$ Å $\alpha = 90^{\circ}$. |
| | $b = 16.2342(7)$ Å $\beta = 90^{\circ}$. |
| | $c = 17.0357(10)$ Å $\gamma = 90^{\circ}$. |
| Volume | 2429.8(2) Å ³ |
| Z | 4 |
| Density (calculated) | 1.387 Mg/m^3 |
| Absorption coefficient | 1.723 mm ⁻¹ |
| F(000) | 1048 |
| Crystal size | 0.15 x 0.12 x 0.10 mm ³ |
| Theta range for data collection | 1.733 to 32.555°. |
| Index ranges | -8<=h<=12,-22<=k<=14,-10<=l<=25 |
| Reflections collected | 14745 |
| Independent reflections | 7325[R(int) = 0.0289] |
| Completeness to theta $=32.555^{\circ}$ | 86.5% |
| Absorption correction | Empirical |
| Max. and min. transmission | 0.847 and 0.788 |
| Refinement method | Full-matrix least-squares on F ² |
| Data / restraints / parameters | 7325/ 56/ 316 |
| Goodness-of-fit on F ² | 1.037 |
| Final R indices [I>2sigma(I)] | R1 = 0.0345, $wR2 = 0.0694$ |
| R indices (all data) | R1 = 0.0456, $wR2 = 0.0727$ |
| Flack parameter | x = -0.007(4) |
| Largest diff. peak and hole | 0.480 and -0.321 e.Å ⁻³ |

Single Crystal X-ray Diffraction Data for compound 5a (synthesized using quinidine-derived PTC catalyst)

X-ray structure determinations: Crystals of compound **5a** were obtained from a mixture of DCM and hexane at 0 degree. The measured crystal was then analyzed by chiral HPLC to confirm the enantiopurity of the sample (see HPLC traces, 98% ee). *Data Collection*. Measurements were made on a Rigaku XtaLab P200 diffractometer equipped with a Pilatus 200K area detector, a Microfocus-HF007 rotating anode with $Mo_{K\alpha}$ radiation, Confocal Max Flux optic and a Cryostream Plus low temperature device (T = 100K). Full-sphere data collection was used with ω and φ scans.



For the absolute configuration determination of the light-atom molecule **5a** the methodology described in the following work has been followed:

The use of Mo Kα radiation in the assignment of the absolute configuration of light-atom molecules; the importance of high-resolution data E. C. Escudero-Adán, J. Benet-Buchholz, P. Ballester Acta Cryst. B, **2014**, 70, 660-668

Crystal data for 5a at 100 K: CCDC 1046069

| Identification code | CV469-1 | |
|--|---|--------------------------------|
| Empirical formula | C14 H14 O2 | |
| Formula weight | 214.25 | |
| Temperature | 100(2) K | |
| Wavelength | 0.71073 Å | |
| Crystal system | Monoclinic | |
| Space group | C2 | |
| Unit cell dimensions | a = 22.183(11)Å | $\alpha = 90^{\circ}$. |
| | b = 7.950(3)Å | $\beta = 122.929(5)^{\circ}$. |
| | c = 15.744(8)Å | $\gamma = 90^{\circ}$. |
| Volume | 2330.6(19) Å ³ | |
| Z | 8 | |
| Density (calculated) | 1.221 Mg/m^3 | |
| Absorption coefficient | 0.081 mm ⁻¹ | |
| F(000) | 912 | |
| Crystal size | 0.20 x 0.20 x 0.20 mm ³ | |
| Theta range for data collection | 3.291 to 52.126°. | |
| Index ranges | -48<=h<=48,-17<=k<=17,-34< | =l<=34 |
| Reflections collected | 70335 | |
| Independent reflections | 25244[R(int) = 0.0226] | |
| Completeness to theta $=52.126^{\circ}$ | 98.1% | |
| Absorption correction | Empirical | |
| Max. and min. transmission | 0.984 and 0.757 | |
| Refinement method | Full-matrix least-squares on F ² | 2 |
| Data / restraints / parameters | 25244/ 1/ 292 | |
| Goodness-of-fit on F ² | 1.053 | |
| Final R indices [I>2sigma(I)] | R1 = 0.0373, $wR2 = 0.0947$ | |
| R indices (all data) | R1 = 0.0497, wR2 = 0.1022 | |
| Flack parameter | x =0.09(10) | |
| Largest diff. peak and hole 0.486 and -0.247 e.Å ⁻³ | | |

I. NMR spectra













































J. HPLC traces





| | 2 | 11.909 | BB | 0.2426 | 4408.78174 | 278.62457 | 99.2987 |
|--|---|--------|----|--------|------------|-----------|---------|
|--|---|--------|----|--------|------------|-----------|---------|



| Peak | RetTime | Туре | Width | Area | Height | Area |
|------|---------|------|--------|-----------|----------|---------|
| # | [min] | I I | [min] | [mAU^s] | [mau] | * 1 |
| 1 | | | 1 | | | 1 |
| 1 | 5.434 | BV | 0.1269 | 699.07312 | 84.15497 | 29.4541 |
| 2 | 5.938 | VB | 0.1999 | 706.72235 | 53.55787 | 29.7764 |
| 3 | 6.807 | BV | 0.1563 | 484.40717 | 47.76132 | 20.4096 |
| 4 | 7.225 | VB | 0.1698 | 483.22598 | 44.10889 | 20.3598 |

Sample Info : IA3, 20°C, 1.0 mL/min, H/DCM 85/15

Additional Info : Peak(s) manually integrated





| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | I |
| 1 | 4.664 | MM | 0.1207 | 698.61780 | 96.46627 | 24.8707 |
| 2 | 6.861 | BB | 0.1529 | 693.47217 | 69.20596 | 24.6875 |
| 3 | 9.196 | VB | 0.2116 | 710.62610 | 51.31746 | 25.2982 |
| 4 | 11.525 | MM | 0.3038 | 706.28168 | 38.74936 | 25.1435 |



2



| , | | 2 | | | 4 | 1 | | 6 | | , | | 8 | |
|-----|--------|------|------|---|-----|---|--|------|---|---|----|-----|---|
| eak | RetTir | ne 1 | 'ype | W | idt | h | | Area | 1 | | Не | iqh | 1 |

0

| Peak | RetTime | туре | Width | Area | Height | Area | |
|------|---------|------|--------|-----------|----------|----------|--|
| # | [min] | | [min] | [mAU*s] | [mAU] | 웡 | |
| | | | | | | | |
| 1 | 5.830 | MM | 0.1536 | 231.52487 | 25.12109 | 100.0000 | |

min

10



| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | |
| 1 | 6.511 | VB | 0.1421 | 1001.88342 | 106.19474 | 21.1139 |
| 2 | 9.560 | BV | 0.2060 | 1341.53601 | 100.34072 | 28.2718 |
| 3 | 10.046 | VB | 0.2185 | 1040.27820 | 72.04583 | 21.9230 |
| 4 | 12.324 | BB | 0.2764 | 1361.44092 | 75.50639 | 28.6913 |





| Peak | RetTime | туре | Width | Area | Height | Area |
|------|---------|------|--------|------------|-----------|---------|
| # | [min] | | [min] | [mAU*s] | [mAU] | % |
| | | | | | | |
| 1 | 6.641 | MM | 0.1407 | 511.78128 | 60.61497 | 12.8551 |
| 2 | 7.496 | BV | 0.1808 | 502.16693 | 42.19896 | 12.6137 |
| 3 | 8.071 | vv | 0.1618 | 1468.41467 | 138.37799 | 36.8843 |
| 4 | 8.517 | VB | 0.1801 | 1498.77588 | 126.62607 | 37.6469 |



| # | [min] | [min] | [mAU*s] | [mAU] | 8 | |
|---|----------|--------|------------|-----------|---------|--|
| | | | | | | |
| 1 | 6.967 MM | 0.2048 | 9293.75684 | 756.45245 | 97.7332 | |
| 2 | 7.866 MM | 0.2401 | 215.55508 | 14.96487 | 2.2668 | |



| Peak | RetTime | Туре | Width | Area | Height | Area |
|------|---------|------|--------|------------|-----------|---------|
| # | [min] | | [min] | [mAU*s] | [mAU] | 8 |
| | | | | | | |
| 1 | 6.946 | BB | 0.2016 | 2059.94434 | 156.45685 | 35.2500 |
| 2 | 17.245 | BV | 0.5100 | 851.82043 | 25.61514 | 14.5764 |
| 3 | 18.709 | VV | 0.5395 | 870.92029 | 24.81473 | 14.9033 |
| 4 | 20.008 | VB | 0.5935 | 2061.13672 | 53.50070 | 35.2704 |



| Peak | RetTime | Туре | Width | Area | Height | Area |
|------|---------|------|--------|------------|-----------|---------|
| # | [min] | | [min] | [mAU*s] | [mAU] | 8 |
| | | | | | | |
| 1 | 6.983 | BB | 0.2118 | 7515.97705 | 548.61072 | 99.5054 |
| 2 | 20.155 | MM | 0.5516 | 37.35805 | 1.12869 | 0.4946 |





| # | [min] | [min] | [mAU*s] | [mAU] | 용 |
|---|----------|--------|-----------|------------|---------|
| | | - | | | |
| 1 | 5.362 MM | 0.1303 | 685.90411 | 87.76635 | 98.7483 |
| 2 | 7.304 MM | 0.1536 | 8.69424 | 9.43345e-1 | 1.2517 |



| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % | |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|--|
| | | | | | | | |
| 1 | 7.965 | BB | 0.2036 | 973.34015 | 72.04575 | 24.2036 | |
| 2 | 17.372 | BV | 0.3749 | 972.00409 | 39.24632 | 24.1704 | |
| 3 | 18.443 | VB | 0.3921 | 1043.04846 | 40.28711 | 25.9370 | |
| 4 | 20.808 | BB | 0.4531 | 1033.06934 | 34.92126 | 25.6889 | |
| | | | | | | | |





| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | |
| 1 | 7.841 | BB | 0.2130 | 1377.96411 | 102.40431 | 15.3565 |
| 2 | 9.641 | BV | 0.2530 | 1353.40515 | 85.36687 | 15.0828 |
| 3 | 10.225 | MM | 0.2968 | 3149.81030 | 176.85168 | 35.1025 |
| 4 | 12.587 | MM | 0.0835 | 3091.99072 | 616.89056 | 34.4582 |



| # | [min] | [min] | [mAU*s] | [mAU] | 8 | |
|---|----------|--------|-----------|-----------|---------|--|
| | | | | | | |
| 1 | 7.772 MM | 0.2425 | 1.30949e4 | 900.06689 | 98.2653 | |
| 2 | 9.374 MM | 0.3430 | 231.16083 | 11.23239 | 1.7347 | |



| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | |
| 1 | 8.293 | BB | 0.2295 | 3144.58594 | 216.40015 | 27.9775 |
| 2 | 10.283 | BB | 0.3046 | 3148.91846 | 159.33759 | 28.0161 |
| 3 | 12.514 | VB | 0.3041 | 2476.00464 | 130.07881 | 22.0291 |
| 4 | 13.566 | MM | 0.1392 | 2470.17017 | 295.83997 | 21.9772 |
| | | | | | | |





| 2 | 5.387 BB | 0.1327 | 722.21149 | 83.64573 | 28.4934 |
|---|----------|--------|-----------|----------|---------|
| 3 | 6.317 VV | 0.1511 | 544.85712 | 56.18079 | 21.4963 |
| 4 | 6.744 VB | 0.1637 | 552.63757 | 52.96164 | 21.8032 |



 1
 6.289 MM
 0.1635
 109.86890
 11.20116
 6.3118

 2
 6.697 MM
 0.1745
 1630.81848
 155.76659
 93.6882



| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | |
| 1 | 6.412 | VV | 0.1595 | 615.41608 | 61.08512 | 92.7110 |
| 2 | 6.786 | VB | 0.1678 | 41.81278 | 5.13327 | 6.2990 |





| Peak | RetTime | Туре | Width | Area | Height | Area |
|------|---------|------|--------|-----------|----------|---------|
| # | [min] | | [min] | [mAU*s] | [mAU] | 8 |
| | | - | - | | | |
| 1 | 5.434 | BV | 0.1269 | 699.07312 | 84.15497 | 29.4541 |
| 2 | 5.938 | VB | 0.1999 | 706.72235 | 53.55787 | 29.7764 |
| 3 | 6.807 | BV | 0.1563 | 484.40717 | 47.76132 | 20.4096 |
| 4 | 7.225 | VB | 0.1698 | 483.22598 | 44.10889 | 20.3598 |





| Peak RetTime Type Width Area Heig # [min] [min] [mAU*s] [mAU | JNT Area J] % |
|---|------------------|
| | |
| 1 4.664 MM 0.1207 698.61780 96.4 | 16627 24.8707 |
| 2 6.861 BB 0.1529 693.47217 69.2 | 20596 24.6875 |
| 3 9.196 VB 0.2116 710.62610 51.3 | 31746 25.2982 |
| 4 11.525 MM 0.3038 706.28168 38.7 | 74936 25.1435 |



| # | [min] | | [min] | [mAU*s] | [mAU] | 웅 |
|---|--------|----|--------|------------|-----------|---------|
| | | | | | | |
| 1 | 9.286 | BB | 0.2072 | 141.60855 | 10.51252 | 5.5754 |
| 2 | 11.388 | MM | 0.3079 | 2398.29224 | 129.83093 | 94.4246 |





| Peak | RetTime | Туре | Width | Area | Height | Area |
|------|---------|------|--------|------------|-----------|---------|
| # | [min] | | [min] | [mAU*s] | [mAU] | 00 |
| | | | | | | |
| 1 | 7.716 | MM | 0.1788 | 289.86420 | 27.02489 | 9.5770 |
| 2 | 8.342 | MM | 0.2039 | 2736.80957 | 223.66562 | 90.4230 |



| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % | |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|--|
| | | | | | | | |
| 1 | 6.511 | VB | 0.1421 | 1001.88342 | 106.19474 | 21.1139 | |
| 2 | 9.560 | BV | 0.2060 | 1341.53601 | 100.34072 | 28.2718 | |
| 3 | 10.046 | VB | 0.2185 | 1040.27820 | 72.04583 | 21.9230 | |
| 4 | 12.324 | BB | 0.2764 | 1361.44092 | 75.50639 | 28.6913 | |
| | | | | | | | |





| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | |
| 1 | 6.641 | MM | 0.1407 | 511.78128 | 60.61497 | 12.8551 |
| 2 | 7.496 | BV | 0.1808 | 502.16693 | 42.19896 | 12.6137 |
| 3 | 8.071 | vv | 0.1618 | 1468.41467 | 138.37799 | 36.8843 |
| 4 | 8.517 | VB | 0.1801 | 1498.77588 | 126.62607 | 37.6469 |



12.38120

0.2049 3276.21045 266.54477 96.3082

3.6918

1 8.913 MM 0.1691 125.58755

2 9.450 MM





2 8.322 MM 0.1997 856.40710 71.47701 88.3538

| S | 50 |
|---|----|
|---|----|



| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | - | | | | |
| 1 | 7.965 | BB | 0.2036 | 973.34015 | 72.04575 | 24.2036 |
| 2 | 17.372 | BV | 0.3749 | 972.00409 | 39.24632 | 24.1704 |
| 3 | 18.443 | VB | 0.3921 | 1043.04846 | 40.28711 | 25.9370 |
| 4 | 20.808 | BB | 0.4531 | 1033.06934 | 34.92126 | 25.6889 |





| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | |
| 1 | 7.841 | BB | 0.2130 | 1377.96411 | 102.40431 | 15.3565 |
| 2 | 9.641 | BV | 0.2530 | 1353.40515 | 85.36687 | 15.0828 |
| 3 | 10.225 | MM | 0.2968 | 3149.81030 | 176.85168 | 35.1025 |
| 4 | 12.587 | MM | 0.0835 | 3091.99072 | 616.89056 | 34.4582 |



| Peak | RetTime | туре | Width | Area | Height | Area |
|------|---------|------|--------|------------|-----------|---------|
| # | [min] | | [min] | [mAU*s] | [mAU] | ÷ |
| | | | | | | |
| 1 | 10.043 | MM | 0.2538 | 80.40902 | 5.28060 | 6.4748 |
| 2 | 12.925 | MM | 0.1496 | 1161.46509 | 129.37723 | 93.5252 |



| Peak # | RetTime [min] | Туре | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|-----------|------------------|------|----------------|-----------------|-----------------|-----------|
| | | | | | | |
| 1 | 8.293 | BB | 0.2295 | 3144.58594 | 216.40015 | 27.9775 |
| 2 | 10.283 | BB | 0.3046 | 3148.91846 | 159.33759 | 28.0161 |
| 3 | 12.514 | VB | 0.3041 | 2476.00464 | 130.07881 | 22.0291 |
| 4 | 13.566 | MM | 0.1392 | 2470.17017 | 295.83997 | 21.9772 |
| | | | | | | |



